Stukov A N, Kharitonova N N, Kulikov A N, Vershinina S F, Murazov Ya G, Zmitrichenko Yu G, Senchik K Yu, Tochilnikov G V, Ermakova E D, Filatova L V, Latipova D Kh, Semiglazova T Yu
N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia.
Military Medical Academy named after S.M. Kirov, Saint Petersburg, Russia.
Vestn Oftalmol. 2022;138(4):6-14. doi: 10.17116/oftalma20221380416.
Eyelid tumors are the most common neoplasms in everyday ophthalmic practice and cover a wide range of benign and malignant lesions. Surgical methods, cryodestruction, laser therapy and radiation therapy are used in the treatment of malignant eyelid tumors. Chemotherapy does not occupy a prominent place in the treatment of malignant eyelid tumors, its use is limited to sensitive tumors.
To assess the antitumor activity of the Russian-developed chemical compound 2-[3-(2-chloroethyl)-3-nitrosoureido]-1.3-propandiol (chlonisol) on the models of transplantable tumors of various histogenesis implanted into the lower eyelid.
The study was carried out on 67 mice of lines 129/SN, BALB/c and C57BL/6 that had Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1 and B16 melanoma transplanted into the eyelid. Tumor transplantation was done by injecting 0.05 ml of sterile sodium chloride solution containing 10 cells of Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1, or 10% suspension of tumor tissue of B16 melanoma. The injection was performed into the right lower eyelid in the direction from the outer towards the inner corner of the eye using a thin needle (29G). Chlonisol was administered at the maximum tolerated dose of 20 mg/kg or at the lower dose of 15 mg/kg intraperitoneally 24 hours after tumor transplantation.
In mice with Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1 and melanoma B16 transplanted under the skin of the lower eyelid, a single intraperitoneal injection of chlonisol at the dose of 20 or 15 mg/kg caused significant inhibition of tumor growth reaching 100%. Chlonisol significantly increased overall survival in animals with Ehrlich carcinoma (log rank test, =0.0464), sarcoma 37 (log rank test, <0.0001), lymphosarcoma LIO-1 (log rank test, =0.0122) and B16 melanoma (log rank test, <0.0001); the proportion of animals that were fully healed was 25, 78, 67 and 25%, respectively.
Chlonisol has a pronounced antitumor effect in mice with Ehrlich carcinoma, sarcoma 37, lymphosarcoma LIO-1 and B16 melanoma transplanted into the eyelid.
眼睑肿瘤是日常眼科实践中最常见的肿瘤，涵盖了广泛的良性和恶性病变。手术方法、冷冻治疗、激光治疗和放射治疗用于治疗恶性眼睑肿瘤。化疗在恶性眼睑肿瘤的治疗中并不占据突出地位，其应用仅限于敏感肿瘤。
评估俄罗斯研发的化合物2-[3-(2-氯乙基)-3-亚硝基脲基]-1,3-丙二醇（氯尼索尔）对植入下眼睑的各种组织发生的可移植肿瘤模型的抗肿瘤活性。
研究在129/SN、BALB/c和C57BL/6品系的67只小鼠上进行，这些小鼠的下眼睑植入了艾氏癌、肉瘤37、淋巴肉瘤LIO-1和B16黑色素瘤。通过注射0.05 ml含有10个艾氏癌细胞、肉瘤37细胞、淋巴肉瘤LIO-1细胞的无菌氯化钠溶液或10%的B16黑色素瘤肿瘤组织悬液进行肿瘤移植。使用细针（29G）从眼外角向内角方向注射到右下眼睑。在肿瘤移植后24小时，以20 mg/kg的最大耐受剂量或15 mg/kg的较低剂量腹腔注射氯尼索尔。
在右下眼睑皮下植入艾氏癌、肉瘤37、淋巴肉瘤LIO-1和黑色素瘤B16的小鼠中，单次腹腔注射20 mg/kg或15 mg/kg剂量的氯尼索尔可显著抑制肿瘤生长，抑制率达100%。氯尼索尔显著提高了艾氏癌（对数秩检验，P = 0.0464）、肉瘤37（对数秩检验，P < 0.0001）、淋巴肉瘤LIO-1（对数秩检验，P = 0.0122）和B16黑色素瘤（对数秩检验，P < 0.0001）动物的总生存率；完全治愈的动物比例分别为25%、78%、67%和25%。
氯尼索尔对植入下眼睑的艾氏癌、肉瘤37、淋巴肉瘤LIO-1和B16黑色素瘤小鼠具有显著的抗肿瘤作用。
